What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants were administered LP-003 via subcutaneous injection every 4 weeks.”In the company’s words, NCT07291284 on ClinicalTrials.gov
- Tested for
- Seasonal Allergic Rhinitis, Chronic Spontaneous Urticaria (CSU), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Food Allergy, Wheat Hypersensitivity, Allergic Asthma, Peanut Allergies, Allergic Diseases and 1 more
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.”In the company’s words, NCT07291284 on ClinicalTrials.gov
Other drugs for Seasonal Allergic Rhinitis
- SHR-1819Hengrui · Phase 3
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
- GR1802Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3
- Rupatifen FumarateFujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 2/3
- PG-011Prime Gene Therapeutics Co., Ltd. · Phase 3
Coming up6
- NovPhase 1 trial completes · ClinicalTrials.gov
- 28 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 16 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 28 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 24 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- May 2029Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07946913
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Mar 2026 | Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis | |
| Phase 3Not yet recruiting | 24 Mar 2028 | A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines | |
| Phase 2Not yet recruiting | 28 Feb 2027 | A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | |
| Phase 2Not yet recruiting | 16 Jul 2027 | A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy | |
| Phase 2Recruiting | 28 Dec 2027 | Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients | |
| Phase 2Not yet recruiting | May 2029 | Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients | |
| Phase 1/2Active, not recruiting | 31 May 2026 | A Study of Single Dose of LP-003 in Adolescent Subjects | |
| Phase 1Active, not recruiting | Nov 2026 | A Study of Single Dose of LP-003 in Healthy Adult Subjects | |
| Phase 2Completed | 19 Oct 2023 | Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult | |
| Phase 2Completed | 17 Apr 2025 | Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment | |
| Phase 1Completed | 4 Mar 2024 | A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026